Source: http://www.wvlegislature.gov/Bill_Status/bills_text.cfm?billdoc=sb580%20intr.htm&yr=2011&sesstype=RS&i=580
Timestamp: 2018-03-17 11:10:10
Document Index: 595233920

Matched Legal Cases: ['§16', '§16', '§16', '§16', '§16', '§16', '§16', '§16', '§16', '§16', '§16', '§16', '§16', '§16', '§16', '§16', '§16', '§16']

[Introduced February 21, 2011; referred to the Committee on Health and Human Resources; and then to the Committee on the Judiciary.]
A BILL to amend the Code of West Virginia, 1931, as amended, by adding thereto a new article, designated §16-43-1, §16-43-2, §16-43-3, §16-43-4, §16-43-5 and §16-43-6, all relating to creating the Medication Therapy Management Act; and specifying that fees for third-party providers pay for the therapy under this act.
That the Code of West Virginia, 1931, as amended, be amended by adding thereto a new article, designated §16-43-1, §16-43-2, §16-43-3, §16-43-4, §16-43-5 and §16-43-6, all to read as follows:
ARTICLE 43. MEDICATION THERAPY MANAGEMENT ACT.
§16-43-1. Medication therapy management program.
A medication therapy management program defined in this article is a program of drug therapy management furnished by a duly licensed pharmacist under the West Virginia Code, and that is designed to assure, with respect to targeted patients that medications are appropriately used to optimize therapeutic outcomes through improved medication use, and to reduce the risk of adverse events, including adverse drug interactions. Such a program may distinguish between services in ambulatory and institutional settings. Upon implementation, third-party providers and state health care providers shall pay a fee to pharmacy providers for medication therapy management services. Targeted patients are individuals who have at least one chronic disease, including, but not limited to, diabetes, asthma, chronic obstructive pulmonary disease or other chronic lung disorders, hypertension, hyperlipidemia, congestive heart failure, chronic pain disorder or behavioral health disorder, and are taking multiple drugs to treat one or more such conditions. A patient with a prescription drug therapy problem who is identified by the primary health care provider and is eligible for medication therapy management services under the plan, self-pay.
§16-43-2. Definition.
§16-43-3. Patient treatment.
(f) Providing consultative services for the patient, intervening to address medication-related issues, and, when the pharmacist believes it will be beneficial to the patient's health, referring the patient to his/her regular health care provider for evaluation and additional referral(s);
(o) Performing follow-up MTM services for the maintenance and support of the patient, as recommended by the primary health care provider and/or other health care professional or specialist; and
(2) Subjective, meaning, patient-reported, information;
(3) Objective, meaning, service provider-based, observations regarding known allergies, diseases, conditions, laboratory test results, vital signs, physical exam results, review of systems, and recorded medical diagnoses;
§16-43-4. Reimbursement eligibility.
To be eligible for reimbursement for services provided under this section, a pharmacist shall:
§16-43-5. Evaluation.
§16-43-6. Payment of fees.
(b)The fee shall be calculated using one or more quarter-hourly rates implemented by formal regulation that are designed to reimburse the pharmacist or pharmacy based on time spent in providing the medication therapy management services.